Rosen Law Firm Advises Applied Therapeutics Investors Before Class Action Deadline

NEW YORK, Dec. 30, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a well-known global investor rights law firm, reminds individuals who bought securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between January 3, 2024, and December 2, 2024 (the "Class Period"), about the crucial February 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Applied Therapeutics securities during the Class Period, you may be eligible for compensation without having to pay any out-of-pocket fees or costs thanks to a contingency fee arrangement.

WHAT TO DO NEXT: To participate in the Applied Therapeutics class action lawsuit, visit this link or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for more information about the class action. A class action lawsuit has already been initiated. If you wish to act as the lead plaintiff, it is necessary to inform the court by February 18, 2025. The lead plaintiff represents other class members in managing the litigation process.

WHY ROSEN LAW: We encourage investors to choose experienced counsel who have a proven track record in leadership roles. Many law firms issuing notices may lack comparable experience, resources, or significant peer recognition. Several of these firms do not actively litigate securities class actions but act merely as intermediaries that refer clients or work with firms that do handle the cases. It's essential to make an informed decision when selecting representation. The Rosen Law Firm assists investors worldwide, focusing primarily on securities class actions and shareholder derivative litigation. They achieved a record settlement in a securities class action against a Chinese company and have been ranked as a leading firm in securities class action settlements since 2013, recovering hundreds of millions of dollars for investors. In 2019, they secured over $438 million for investors. In recognition of their work, founding partner Laurence Rosen was named a Titan of the Plaintiffs’ Bar by Law360 in 2020. Several attorneys from the firm have received accolades from Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The lawsuit claims that statements made during the class period were false and/or misleading because they obscured and misrepresented the clinical trial protocols and procedures followed by Applied Therapeutics. Consequently, defendants portrayed an inaccurate impression that appropriate protocols and good clinical practices were being adhered to. The lawsuit contends that, in reality, Applied Therapeutics was not following trial protocols or good clinical practices, significantly increasing the risk that the trial data would be rejected by the U.S. Food and Drug Administration (FDA) in the context of a New Drug Application. Once the true information became public, it allegedly caused investors to incur losses.

To engage in the Applied Therapeutics class action, please visit this link, call Phillip Kim, Esq. toll-free at 866-767-3653, or email [email protected] for further details on the class action.

No class has been certified at this time. Until a class is certified, you are not represented by counsel unless you retain one. You can choose any counsel you prefer, and you may also choose to remain an absent class member and take no action for now. An investor's potential to benefit from any future recovery is not contingent on their role as lead plaintiff.

For updates, follow us on LinkedIn or Twitter.

Attorney Advertising. Previous results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

www.rosenlegal.com

Rosen, Law, Class, Action, Investors